New Combo Pill Offers Hope to Hepatitis C Patients Who Fail Other Treatment

3-drug mixture was nearly 100 percent effective in drug company trials WEDNESDAY, May 31, 2017 (HealthDay News) -- A pill that contains three powerful antiviral drugs might offer a cure for many hepatitis C patients who have failed other treatments, researchers report. The pill -- which contains the antiviral drugs sofosbuvir (Sovaldi), velpatasvir and voxilaprevir -- was nearly 100 percent effective in curing hepatitis C in patients whose disease retu...

Black, Hispanic HCV patients more likely to fail DAA therapy

Black and Hispanic patients with hepatitis C virus infection were less likely to achieve sustained virologic response with direct-acting antiviral agents compared with white patients within the U.S. Veterans Affairs health care system, according to recent study results. Further, black patients with HCV genotype 1 infection who were treated with Harvoni (ledipasvir/sofosbuvir, Gilead) monotherapy were significantly less likely to achieve SVR compared with